Document is current
Any future updates will be listed below
-
Authors
Stockfelt, Marit https://orcid.org/0000-0002-4438-4849
Teng, Y. K. Onno https://orcid.org/0000-0001-9920-2195
Vital, Edward M. https://orcid.org/0000-0003-1637-4755
- License Information
-
More Information
Article History
Accepted: 5 December 2024
First Online: 15 January 2025
Competing interests
: M.S. declares no competing interests. E.M.V. has received consultancy fees from Roche, GSK, AstraZeneca, UCB, Otsuka, BMS, Pfizer, Abbvie, Pfizer, Alpine, Alumis, Merck, BMS, Aurinia Pharmaceuticals, Lilly and Novartis, and has also received research grants paid to his employer from AstraZeneca and Sandoz. Y.K.O.T. has received grants/research support from the Dutch Arthritis Foundation, Autoimmune Research & Collaboration (ARCH) Foundation, Dutch Kidney Foundation, Netherlands Organization for Scientific Research, GSK, CSL Vifor and LUMC, and has received consulting fees from AstraZeneca, Alexion, GSK, Novartis, Otsuka Pharmaceuticals and Vifor Pharma.
